 |
 |
 |
|
|
|
November 18th, 2008
Nephrology Quiz and Questionnaire: Fluid and Electrolyte and Glomerulonephritis Cases 
Michael Emmett, MD, and Jai Radhakrishnan, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Emmett: Case 2: Was it laxative that the patient drank? The wife said it was magnesium citrate. Anyway, now he's comatose with normal electrolytes. Then his creatinine goes up and his serum osmolality does, also, with positive ketones, but no acidosis. How would you treat him? Case 6: A woman who takes Topamax for migraines presents with hyponatremia and hyperchloremic acidosis. How does topiramate affect the kidney and what indications is it being used for? Radhakrishnan: Case 4: Young AA woman with nephrotic syndrome and elevated ANA. OK, it's membranous: lupus or not? If lupus, how do we treat it? Case 8: Middle-aged female with acute fulminant GN picture and a creatinine of 10. Is it worth treating her? What if she has anti-GBM? What if she has MPO-ANCA? .
Preparing for the New Medical Director Responsibilities 
Flash - slide/audio and MP3 audio
(Network 9/10 - RPA Special Symposium. October 2008.)
Overview and Introduction to the Nework Role in QAPI and CMS Compliance
Peter B. DeOreo, MD (Introduced by George Aronoff, MD and Alan S. Kliger, MD)
QAPI: Quality and Safety - The Big Picture
Alan S. Kliger, MD
The Medical Director, the IDT and the Medical Staff
J. Michael Lazarus, MD
Governance, Administrative and Supervisory Issues for the Medical Director under the New CfC
David Van Wyck, MD
Legal Implications for the Medical Director Under the New CfC
James Riley, Jr.
Panel Discussion: Rebuttals, Rejoinders and Reality
Drs. De Oreo, Kliger, Van Wyck, Lazarus and Mr. Riley. Moderators: Drs. Aronoff and Wish
Water: What's New and What to Do (Parts 1 and 2)
James Baker
(Dr. Priti Patel's talk to be added soon).
Biopsy Conference: A 60-year-old male with chronic lymphocytic leukemia and nephrotic syndrome
(Columbia University Nephrology and Pathology Faculty; October, 2008)
Male with chronic lymphocytic leukemia with increasing proteinuria over 2.5 years, from 0.8 to 1.4 to 7.2 g/day. Serum creatinine is 1.3 mg/dL with negative serologies. What is the differential diagnosis and how would you treat him?
(Edited by Jai Radhakrishnan, MD). (more...)
Annual Dialysis Conference 2008
now in MP3AUDIOFILE LIST (Annual Dialysis Conference 2008)
(16 talks)
Towards Animal Model Standardization in PD
Andrzej Breborowicz, MD., Bengt Lindholm, MD., Harold Moore, MA.,Andrzej Breborowicz, MD., Dirk Struijk, MD
The Evidence and Practice of HD
Madhukar Misra, MD., Christopher Chan, MD., Amit Sharma, MD
Theory and Practice of Anticoagulation
Anaadriana Zakarija, MD., Andrew Davenport, MD., Karl-Georg Fischer, MD., Suhail Ahmad, MD
PD and HD Controversies
Anatole Besarab, MD., Brendan McCormick, MD.,Brendan McCormick, MD., Salim Mujais, MD
Managing Comorbidites in PD Patients
Kul Aggarwal, MD., Pranay Kathuria, MD., Kamyar Kalantar-Zadeh, MD., Thomas Golper, MD
Did you miss these recent slide/audio lectures?
Controversies in Diagnosis and Treatment of Atherosclerotic Renovascular Disease
Stephen C. Textor, MD and Lance D. Dworkin, MD, FASN
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Textor: What is significant renovascular disease? How do nephrologists vs. cardiologists vs. radiologists differ in their perspectives on this condition? What are the statistics regarding use of endovascular renal artery stenting? How does interventional treatment vary by geography? At what level of pressure drop does a stenosis affect renin levels? How do renal vascular lesions affect cardiovascular outcome? Renal outcome? Dworkin: How common is renal artery stenosis? How does it associate with other comorbidities? Survival? What are common justifications for its treatment? What are the main randomized trials of intervention vs. medical management and what did they show? What are their shortcomings? Why don't all patients respond to renin blockade? What is the impact of intervention on renal function? Does GFR correlate with extent of stenosis. Is flash pulmonary edema really related to renal artery stenosis? What about congestive heart failure? What is optimal medical therapy? What is the CORAL study and what is it designed to evaluate? How can we refer patients to this study? Note: The other 2 talks from this CNC are avaiable as audiofiles at this link.
New Insights, Treatments, and Management Strategies for ADPKD
Arlene B. Chapman, MD, and James P. Calvet, PhD
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Chapman: What was the design of the CRISP study in ADPKD patients? How was progression measured? What factors are known to be associated with progression? How was cyst size measured? How did the investigators get by without gadolinium? What were factors predicting increase in cyst volume? What was found regarding liver cysts? PKD-1 vs. PKD-2? How is the renin-angiontensin system involved in ADPKD? What was the design of the HALT PKD study? What was the rationale for dual blockade? Is concomitant aldosterone blockade indicated? Calvet: What are the strategies to inhibit cyst formation in ADPKD? What are potential methods of inhibiting cell proliferation? Cyst secretion? How are CFTR and NKCC-1 involved? Is cyclic AMP good or bad for PKD? What about bumetanide? How does intracellular calcium act to affect cell proliferation? What are potential implications regarding calcium channel blockers? What are the data about manipulating B-Raf, MEK, and ERK? Note: The other 2 talks from this CNC are avaiable as audiofiles at this link.
What You Can Teach Your Team About Chronic Kidney Disease-Related Mineral Bone Disorder (CKD-MBD)
Rebecca Schmidt, DO, FACP, FASN and Sharon Senft, RN-C, FNP
(ANNA National Symposium, Philadelphia, PA. April, 2008.) 1.5 CNE
Dr. Schmidt and Ms. Senft: Part One: What is happening to the prevalence of CKD? What is the incidence by race and ethnicity? What are the associated conditions? How many millions have CKD? Are they aware of it? Who is at greatest risk? What did we find in West Virginia? What can we learn from the case of a young diabetic with CKD? Part Two: What is this young patient's likely outcome? His mortality risk? What is the risk for hospitalization due to congestive heart failure? Expected remaining lifetime? How do serum calcium and serum phosphorus relate to mortality risk? What about the coronary artery calcification score? How can one assess vascular calcification? Part Three: How can we optimize outcome by intervening early in CKD- related mineral bone disorder? How can we achieve optimal bone health and minimize risk for vascular calcification? How do we manage a case with high serum phosphorus and high serum calcium? What about a case with high phosphorus and low serum calcium? When do we combine binders? What are the challenges in managing hyperphosphatemia? What is the calcium balance associated with various calcium baths? What are the advantages and disadvantages of each class of phosphate binders? What are their comparative efficacies? What is sevelamer carbonate and why might it be an improved binder? What can you teach your team about CKD-related bone mineral disorder (CKD-MBD)?
Did you miss these recent audiofile lectures?
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
(43 talks - last batch!)
Controversies in Diagnosis and Treatment of Atherosclerotic Renovascular Disease
SC Textor, BF King, LD Dworkin, SL Linas
The Genetics of FSGS
F Hildebrandt, AN Vats, F Kaskel
Nephrolithiasis 2007
EM Worcester, JC Lieske, AP Evan
No Patient Left Behind: Issues in Renal Transplantation
AB Leichtman, RS Gaston, RB Mannon, DJ Cohen
Novel Therapeutics for Fluid and Electrolyte Disorders
RW Schrier, P Gross, JG Verbalis, BF Palmer
What the Nephrologist Should Know about Vascular Access
JJ Sands, AQ Urbanes, A Asif, J Work
Basic Science for Clinicians: Cardiovascular Disease for the Nephrologist
JR Sowers, CS Wilcox, RM Mortensen, M Levi,
Renal Disease and the Metabolic Syndrome
P Muntner, KJ Mather, LF Fried
Public Policy Session: Nephrology Practice in the "Grey Zone": Exploring Industrial Influence in Clinical Practice
AS Kliger, DB Van Wyck, JP Kassirer,
Public Policy Board Forum: The Past, Present, and Future of Clinical Nephrology
J Himmelfarb, AR Nissenson, PB DeOreo, BM Straube
United States Renal Data System (USRDS) - Assessment of Quality of Care of the ESRD Population
PW Eggers, AJ Collins, RN Foley, BL Kasiske, NG Kutner
Plenary Session: Presidential Address (WL Henrich); John P. Peters Award (G Remuzzi); Genome Sequence Variation and the Inherited Basis of Type 2 Diabetes (D Altshuler)
Wl Henrich, G Remuzzi, D Altshuler
HDCN home /about our site / subscribe to key zone / register for free zone
update email
address / subscription status / forget your
password?
